Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

This study is testing whether adding glutathione — a powerful natural antioxidant — to standard immunotherapy (an anti-PD-1 drug) and chemotherapy can improve outcomes for patients with advanced non-small cell lung cancer (NSCLC) whose cancer has progressed after initial treatment. The idea is that glutathione may help the immune system work better against cancer and reduce treatment side effects. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with advanced lung cancer (squamous cell carcinoma or adenocarcinoma, confirmed by biopsy) - Your cancer has grown or spread after receiving first-line chemotherapy or chemo-immunotherapy - You are well enough to receive further treatment **You may NOT be eligible if...** - You have small cell lung cancer or another type of lung cancer (other than squamous or adenocarcinoma) - You have been lost to prior follow-up or cannot commit to study visits - You have serious organ problems that would make chemotherapy or immunotherapy unsafe - You are pregnant or breastfeeding - You are currently enrolled in another clinical trial for lung cancer treatment Talk to your doctor to see if this trial is right for you.